Procalcitonine : Quelles utilisations en pédiatrie ?
Mots-clés :
Procalcitonine, pédiatrie, infection, diagnostic.Résumé
Pro hormone de la calcitonine, la procalcitonine (PCT) est normalement produite par les cellules parafolliculaires de la thyroïde. En cas d’inflammation systémique, surtout si elle est causée par une infection bactérienne, la PCT est produite en grande quantité́ par plusieurs autres types de cellules. C’est un biomarqueur inflammatoire précoce augmentant en général en moins de 6 heures après une agression bactérienne. C’ est un biomarqueur dynamique et spécifique de l’infection bactérienne . En pédiatrie, l'utilisation de la PCT peut être d'une grande valeur. Elle peut être un outil précieux pour détecter précocement une infection bactérienne chez les enfants présentant des symptômes non spécifiques tels que la fièvre. Elle peut aider à différencier les infections bactériennes des infections virales ou d’une inflammation systémique non infectieuse La PCT peut être utilisée pour évaluer la sévérité des infections bactériennes, en particulier dans les cas de sepsis et infections bactériennes systémiques. Il est essentiel de noter que la PCT ne doit pas être utilisée de manière isolée pour prendre des décisions cliniques, elle doit être interprétée en fonction du contexte clinique
Références
Becker KL, Nylen ES, White JC, Muller B, Snider RH, Jr. Clinical
review 167: Procalcitonin and the calcitonin gene family of
peptides in inflammation, infection, and sepsis: a journey from
calcitonin back to its precursors. J Clin Endocrinol Metab 2004;
:1512–25.
D. N. Gilbert. Use of plasma procalcitonin levels as an adjunct to
clinical microbiology. Journal of Clinical Microbiology, vol. 48,
no. 7, pp. 2325–2329, 2010.
Gaillard O. La procalcitonine (PCT). Immuno anal Biol Spéc
;17:82-4.
Weglohner W, Struck J, Fischer-Schulz C, Morgenthaler NG,
Otto A, Bohuon C, et al. Isolation and characterization of serum
procalcitonin from patients with sepsis. Peptides 2001;22: 2099–
Copp DH, Davidson AG. Direct humoral control of parathyroid
function in the dog. Proc Soc Exp Biol Med 1961;107: 342–4.
Linscheid P,Seboek D,Nylen ES,LangerI,Schlatter M,Becker
KL, et al. In vitro and in vivo calcitonin gene expression in parenchymal
cells: a novel product of human adipose tissue. Endocrinology
;144:5578–84.
Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin
in iatrogenic sepsis. Intensive Care Med. 1998 Aug;24(8):888-9.
Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau
GE, Vadas L, Pugin J; Geneva Sepsis Network. Diagnostic value
of procalcitonin, interleukin-6, and interleukin-8 in critically ill
patients admitted with suspected sepsis. Am J Respir Crit Care
Med. 2001 Aug 1;164(3):396-402.
M. Stocker, W. Van Herk, S. El Helou, et al. Procalcitonin-guided
decision making for duration of antibiotic therapy in neonates
with suspected early-onset sepsis: a multicentre, randomised
controlled trial (NeoPIns), Lancet 390 (2017) 871–881.
Byington CL, Enriquez FR, Hoff C, Tuohy R, Taggart EW, Hillyard
DR, et al. Serious bacterial infections in febrile infants
to 90 days old with and without viral infections. Pediatrics.
;113(6):1662–6.
Byington CL, Reynolds CC, Korgenski K, Sheng X, Valentine
KJ, Nelson RE, et al. Costs and infant outcomes after implementation
of a care process model for febrile infants. Pediatrics.
;130(1):e16–24.
Gomez B, Bressan S, Mintegi S, Da Dalt L, Blazquez D, Olaciregui
I, et al. Diagnostic value of procalcitonin in well-appearing
young febrile infants. Pediatrics. 2012;130(5):815–22.
Gomez B, Bressan S, Mintegi S, Da Dalt L, Blazquez D, Olaciregui
I, de la Torre M, Palacios M, Berlese P, Ruano A. Diagnostic
value of procalcitonin in well-appearing young febrile infants.
Pediatrics. 2012 Nov;130(5):815-22.
Milcent K, Faesch S, Gras-Le Guen C, Dubos F, Poulalhon C,
Badier I, Marc E, Laguille C, de Pontual L, Mosca A, Nissack G,
Biscardi S, Le Hors H, Louillet F, Dumitrescu AM, Babe P, Vauloup-
Fellous C, Bouyer J, Gajdos V. Use of Procalcitonin Assays
to Predict Serious Bacterial Infection in Young Febrile Infants.
JAMA Pediatr. 2016 Jan;170(1):62-9.
M. Assicot, D. Gendrel, H. Carsin, J. Raymond, J. Guilbaud, and
C. Bohuon, “High serum procalcitonin concentrations in patients
with sepsis and infection,” The Lancet, vol. 341, no. 8844, pp.
–518, 1993.
J. C. Marshall and K. Reinhart, “Biomarkers of sepsis,” Critical
Care Medicine, vol. 37, no. 7, pp. 2290–2298, 2009.
C. Rey, M. Los Arcos, A. Concha et al., “Procalcitonin and Creactive
protein as markers of systemic inflammatory response
syndrome severity in critically ill children,” Intensive Care Medicine,
vol. 33, no. 3, pp. 477–484, 2007.
B.Isidor, G.Caillaux, V.Gilquinetal.“The use of procalcitonin in
the diagnosis of late-onset infection in neonatal intensive care
unit patients,” Scandinavian Journal of Infectious Diseases, vol.
, no. 11-12, pp. 1063–1066, 2007.
L. Simon, P. Saint-Louis, D. K. Amre, J. Lacroix, and F. Gauvin,
“Procalcitonin and C-reactive protein as markers of bacterial
infection in critically ill children at onset of systemic inflammatory
response syndrome,” Pediatric Critical Care Medicine, vol.
, no. 4, pp. 407–413, 2008.
J. Casado-Flores, A. Blanco-Quiro ́s, J. Asensio, E. Arranz, J. A.
Garrote, and M. Nieto, “Serum procalcitonin in children with
suspected sepsis: a comparison with C-reactive protein and neutrophil
count,” Pediatric Critical Care Medicine, vol. 4, no. 2, pp.
–195, 2003.
C. Wacker, A. Prkno, F. M. Brunkhorst, and P. Schlattmann, “Procalcitonin
as a diagnostic marker for sepsis: a systematic review
and meta-analysis” The Lancet Infectious Diseases, vol. 13, no.
, pp. 426–435, 2013.
J. PIÉRART, P. LEPAGE Utilité du «Bacterial Meningitis Score»
(BMS) dans le diagnostic différentiel des méningites bactériennes
et virales. Rev Med Liege 2006; 61 : 7-8 : 581-585
Nigrovic LE, Malley R, Kuppermann N. Cerebrospinal fluid
pleocytosis in children in the era of bacterial conjugate vaccines.
Pediatr Emerg Care 2009;25:112–7.
Castelblanco RL, Lee M, Hasbun R. Epidemiology of bacterial
meningitis in the USA from 1997 to 2010: a population-based
observational study. Lancet Infect Dis 2014;14:813–9.25. Dubos F, Lamotte B, Bibi-Triki F, et al. Clinical decision rules
to distinguish between bacterial and aseptic meningitis. Arch DisChild 2006;91:647–50.
Dubos F, Korczowski B , Aygun D , Martinot A et al. Serum
Procalcitonin Level and Other Biological Markers to Distinguish
Between Bacterial and Aseptic Meningitis in Children Arch
Pediatr Adolesc Med. 2008;162(12):1157-1163
Garcia S, Echevarri J, Arana-Arri E, et al. Emerg Med J
;0:1–6.
PrincipiN ES. Biomarkers in pediatric community-acquired
pneumonia. Int J Mol Sci. 2017;18:447.
Lee JY, Hwang SJ, Shim JW, Jung HL, Park MS, Woo HY,
Shim JY. Clinical significance of serum procalcitonin in patients
with community-acquired lobar pneumonia. Korean J Lab Med.
;30:406–13.
Stockmann C, Ampofo K, Killpack J, Williams DJ, Edwards
KM, Grijalva CG, et al. Procalcitonin accurately identifies hospitalized
children with low risk of bacterial community-acquired
pneumonia. J Pediatric Infect Dis Soc. 2018;7:46–53.
SalluhJIF, Souza-Danta VC, Povo P. The current status of biomarkers
for the diagnosis of nosocomial pneumonias. CurrOpin-
Crit Care. 2017; 23:000–000.
Mahajan P, Grzybowski M, Chen X, Kannikeswaran N, Stanley
R, Singal B, et al. Procalcitonin as a marker of serious bacterial
infections in febrile children younger than 3 years old. AcadEmerg
Med. 2014;21:171–9.
Zhu F, Wei H, Li W. Significance of serum procalcitonin levels in
differential diagnosis of pediatric pneumonia. Cell BiochemBiophys.
;73:619–22.
Agnello L, Bellia C, Di Gangi M, Lo Sasso B, Calvaruso L,
Bivona G, et al. Utility of serum procalcitonin and C-reactive
protein in severity assessment of community-acquired pneumonia
in children. Clin Biochem. 2016;49:47–50.
Toikka P, Irjala K, Juven T, Virkki R, Mertsola J, Leinonen
M, Ruuskanen O. Serum procalcitonin, C-reactive protein and
interleukin-6 for distinguishing bacterial and viral pneumonia in
children. Pediatr Infect Dis J. 2000;19:598–602.
Luaces-Cubells C, Mintegi S, García-García JJ, Astobiza E, Garrido-
Romero R, Velasco-Rodríguez J, Benito J. Procalcitonin to
detect invasive bacterial infection in non-toxic-appearing infants
with fever without apparent source in the emergency department.
Pediatr Infect Dis J. 2012;31:645–7.
Esposito S, Tagliabue C, Picciolli I, Semino M, Sabatini C,
Consolo S, et al. Procalcitonin measurements for guiding
antibiotic treatment in pediatric pneumonia. Respir Med.
;105:1939–45.
Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary
tract infection in childhood: a meta-analysis. Pediatr Infect
Dis J Apr 2008;27:302e8.
Hoberman A, Charron M, Hickey RW, Baskin M, Kearney DH,
Wald ER. Imaging studies after a first febrile urinary tract infection
in young children. N Engl J Med 2003; 348:195e202.
Shaikh N, Ewing AL, Bhatnagar S, Hoberman A. Risk of renal
scarring in children with a first urinary tract infection: a systematic
review. Pediatrics 2010; 126:1084e91.
Wennerstrom M, Hansson S, Hedner T, Himmelmann A, Jodal
U. Ambulatory blood pressure 16-26 years after the first urinary
tract infection in childhood. J Hypertens 2000; 18:485e91.
Lahdes-Vasama T, Niskanen K, Ro ̈nnholm K. Outcome of kidneys
in patients treated for vesicoureteral reflux (VUR) during
childhood. Nephrol Dial Transplant 2006;21:2491e7. Jacobson
SH, Eklo ̈f O, Eriksson CG, Lins LE, Tidgren B, Winberg J.
Development of hypertension and uraemia after pyelonephritis
in childhood: 27 year follow up. BMJ 1989;299: 703e6.43. Gervaix A, Geletto-Lacour A, Gueron T, Vadas L, Zamora S,
Suter SGE. Use- fulness of procalcitonin and C-reactive protein
rapid tests for the management of children with urinary tract
infection. Pediatr Infect Dis J. 2001;20:507–511
Liao PF, Ku MS, Tsai JD, et al. Comparison of procalcitonin
and different guidelines for first febrile urinary tract infection in
children by imaging. Pediatr Nephrol. 2014;29:1567–1574.
Shaikh KJ, Osio VA, Leeflang MM, Shaikh N. Procalcitonin, Creactive
protein, and erythrocyte sedimentation rate for the diagnosis
of acute pyelonephritis in children. Cochrane Data- base
Syst Rev 2020;9:CD009185.
J. J. Cies and A. Chopra, “Procalcitonin use in a pediatric intensive
care unit,” Pediatric Infectious Disease Journal, vol. 33, no.
, pp. 984–986, 2014
